Watch for the SNO presentation on November 13, 2026, which will include updated clinical data from the REGAIN trial. Positive efficacy or safety data could significantly de-risk the program and support future regulatory submission discussions.
Price Chart
Executive Summary
Alpha Tau Medical announced FDA approval of an IDE supplement expanding its REGAIN trial for recurrent glioblastoma from 10 to 20 patients, adding new endpoints and an interim analysis. An abstract with updated clinical data has been accepted for presentation at the SNO 2026 Annual Meeting in November. This is a positive regulatory and data catalyst for the company's lead Alpha DaRT platform in a high-need indication.
Key Facts
- FDA approved IDE supplement expanding REGAIN trial enrollment from 10 to 20 patients at three U.S. academic cancer centers.
- Updated protocol adds progression-free survival as a secondary endpoint, quality-of-life assessments, and an additional interim analysis six months after the fifth patient's treatment (July 2026).
- Abstract accepted for presentation at SNO 2026 Annual Meeting (Nov 12-15, Philadelphia) with new trial data building on prior interim results from first three patients.
- Study now also open to patients with IDH-mutant grade 4 tumors, expanding the addressable patient population.
- Glioblastoma is the most common malignant primary brain tumor in the U.S. with extremely limited treatment options.
Financial Impact
No financial figures disclosed; trial expansion and SNO presentation are clinical milestones, not revenue-generating events.
Risk Factors
- Alpha DaRT is not yet approved for any indication; regulatory path remains uncertain.
- Small sample size (up to 20 patients) limits statistical power; early data may not predict final results.
- Company has limited operating history and has incurred significant losses; may need additional funding.
- Competing treatments and clinical trials for recurrent glioblastoma exist.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $12.90 | awaiting T+60 | awaiting T+60 | $13.51 (+4.73%) |
Oct 22, 2026 5d ago | Press Release | $12.90 | awaiting T+60 | awaiting T+60 | $13.51 (+4.73%) |
Oct 19, 2026 8d ago | 6-K | $12.62 | awaiting T+60 | awaiting T+60 | $13.51 (+7.05%) |
Oct 19, 2026 8d ago | Press Release | $12.62 | awaiting T+60 | awaiting T+60 | $13.51 (+7.05%) |
Aug 31, 2026 8w ago | 6-K | $14.11 | awaiting T+60 | awaiting T+60 | $13.51 (−4.25%) |
Aug 10, 2026 11w ago | 6-K | $14.27 | awaiting T+60 | awaiting T+60 | $13.51 (−5.33%) |
Aug 10, 2026 11w ago | Press Release | $14.27 | awaiting T+60 | awaiting T+60 | $13.51 (−5.33%) |
Aug 10, 2026 11w ago | 6-K | $13.60 | awaiting T+60 | awaiting T+60 | $13.51 (−0.66%) |
Jul 21, 2026 14w ago | 6-K | $13.32 $13.74 | ▲ +3.15% | ▼ −0.82% | $13.51 (+1.43%) |
Jul 15, 2026 14w ago | 6-K | $12.46 $14.00 | ▲ +12.36% | ▲ +9.83% | $13.51 (+8.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers